Learning more from the dabigatran concentrations in the RE-LY study

Journal of the American College of Cardiology

Volumn 63, Issue 24, 2014, Pages 2746-2747

  Chin, Paul K L ^a   Wright, Daniel F B ^a   Doogue, Matthew P ^a   Begg, Evan J ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

DABIGATRAN; DABIGATRAN ETEXILATE;

ANTICOAGULANT THERAPY; BLEEDING; BLOOD SAMPLING; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; DIABETES MELLITUS; DRUG BLOOD LEVEL; EMBOLISM; HEART ATRIUM FIBRILLATION; HUMAN; LETTER; PRIORITY JOURNAL; RISK FACTOR; SYSTEMIC EMBOLIC EVENT; UNSPECIFIED SIDE EFFECT; LONG TERM CARE; MINIMUM PLASMA CONCENTRATION; RISK REDUCTION; TIME;

ANTITHROMBINS; BENZIMIDAZOLES; FEMALE; HEMORRHAGE; HUMANS; MALE; PYRIDINES; STROKE;

EID: 84902603189     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2013.11.069     Document Type: Letter

References (8)

1. P.A. Reilly, T. Lehr, S. Haertter RE-LY Investigators The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients in the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy) J Am Coll Cardiol 63 2014 321 328
2. S.J. Connolly, M.D. Ezekowitz, and S. Yusuf et al. Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 2009 1139 1151
3. J. Stangier, K. Rathgen, H. Stahle, and D. Mazur Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study Clin Pharmacokinet 49 2010 259 268
4. S. Hartter, R. Sennewald, G. Nehmiz, and P. Reilly Oral bioavailability of dabigatran etexilate (Pradaxa(®)) after co-medication with verapamil in healthy subjects Br J Clin Pharmacol 75 2013 1053 1062
5. S. Hartter, M. Koenen-Bergmann, and A. Sharma et al. Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin Br J Clin Pharmacol 74 2012 490 500
6. J. Stangier, H. Stahle, K. Rathgen, and R. Fuhr Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects Clin Pharmacokinet 47 2008 47 59
7. M.V. Huisman, G.Y. Lip, H.C. Diener, M. Brueckmann, J. van Ryn, and A. Clemens Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice Thromb Haemost 107 2012 838 847
8. J.W. Eikelboom, S.J. Connolly, and R.G. Hart et al. Balancing the benefits and risks of 2 doses of dabigatran compared with warfarin in atrial fibrillation J Am Coll Cardiol 62 2013 900 908